<DOC>
	<DOCNO>NCT00100997</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin , work different way stop growth cancer cell , either kill cell stop dividing . It may also stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin treating patient chronic phase chronic myelogenous leukemia respond imatinib mesylate .</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond Imatinib Mesylate</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) , term frequency , severity , duration treatment-emergent adverse event , patient imatinib mesylate-resistant Philadelphia chromosome ( Ph ) -positive chronic phase chronic myelogenous leukemia . - Determine pharmacokinetics drug primary metabolite ( 17-amino-17-demethoxygeldanamycin ) patient . Secondary - Determine hematologic response rate , term WBC count , platelet count , assessment blast cell peripheral blood , patient treat drug . - Determine cytogenic response rate , term Ph-positive progenitor cell bone marrow , patient treat drug . - Assess effect drug pharmacodynamic marker ( i.e. , CRKL phosphorylation , BCR-ABL kinase activity , BCR-ABL , RAF kinase , HSP70 expression ) patient . OUTLINE : This open label , dose-escalation , multicenter study . Patients receive 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) IV 15 minute 1 hour ( depend dose administer ) day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 . Treatment repeat every 28 day 3 course absence unacceptable toxicity disease progression . Eligible patient may receive additional course 17-AAG discretion investigator . Cohorts 3-6 patient receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 10 additional patient treat MTD . Patients follow 1 month . PROJECTED ACCRUAL : Approximately 40 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic phase chronic myelogenous leukemia Philadelphia chromosome ( Ph ) positive disease Hematologic resistence treatment imatinib mesylate ( 400 mg per day maximum tolerate dose [ MTD ] ) define 1 follow criterion : Loss complete hematologic response , define WBC count OR platelet count &gt; upper limit normal ( ULN ) 2 separate occasion least 2 week apart attribute etiology Absolute increase â‰¥ 30 % Phpositive cell stable dose imatinib mesylate least 6 months* NOTE : *Patients meet criterion eligible enrollment expand MTD cohort Less 15 % blast peripheral blood bone marrow AND &lt; 30 % blast promyelocytes peripheral blood bone marrow PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic See Disease Characteristics Hepatic Bilirubin &lt; 1.5 time ULN ( 3 mg/dL patient Gilbert 's syndrome ) ALT AST &lt; 2 time ULN No known hepatitis positivity Renal Creatinine &lt; 1.5 time ULN OR Creatinine clearance &gt; 60 mL/min Cardiovascular No New York Heart Association class III IV cardiac disease Pulmonary No severe debilitate pulmonary disease , include follow : Dyspnea rest Significant shortness breath Chronic obstructive pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study participation No known HIV positivity No psychological social condition would preclude study compliance No addictive disorder would preclude study compliance No family problem would preclude study compliance No known allergy sensitivity soy excipient component study drug No illness condition may affect safety study treatment evaluation study endpoint PRIOR CONCURRENT THERAPY : Biologic therapy More 2 week since prior interferon No concurrent interferon Chemotherapy More 2 week since prior cytarabine ( 4 week dose &gt; 100 mg ) More 6 week since prior busulfan No concurrent cytarabine No concurrent hydroxyurea second study treatment course beyond No concurrent anagrelide second study treatment course beyond Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other More 2 day since prior imatinib mesylate More 1 week since prior concurrent drug alter metabolism cytochrome P450 3A4 , include follow : Diltiazem Nifedipine Verapamil Fluconazole Itraconazole Ketoconazole Lovastatin Simvastatin Indinavir Nelfinavir Ritonavir Alprazolam Diazepam Midazolam Triazolam Phenobarbital Phenytoin Carbamazepine Azithromycin Clarithromycin Erythromycin Rifampin Rifamycin Astemizole Terfenidine Amiodarone Cimetidine Cisapride Cyclosporine Grapefruit juice Hypericum perforatum ( St. John 's wort ) Warfarin More 4 week since prior investigational drug recover No concurrent imatinib mesylate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
</DOC>